nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Hallucination—Carmustine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Naltrexone—Dyspnoea—Fludarabine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Naltrexone—Connective tissue disorder—Carmustine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Naltrexone—Ulcer—Methotrexate—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Naltrexone—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Naltrexone—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Naltrexone—Decreased appetite—Fludarabine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Naltrexone—Fatigue—Fludarabine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Naltrexone—Hallucination—Vincristine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Naltrexone—Constipation—Fludarabine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Naltrexone—Pain—Fludarabine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Naltrexone—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Naltrexone—Eye disorder—Carmustine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Naltrexone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Naltrexone—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Naltrexone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Naltrexone—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Naltrexone—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Naltrexone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Naltrexone—Asthenia—Teniposide—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Naltrexone—Malaise—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Naltrexone—Pruritus—Teniposide—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Naltrexone—Cardiac disorder—Vincristine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Naltrexone—Alopecia—Carmustine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Naltrexone—Body temperature increased—Fludarabine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Naltrexone—Mental disorder—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Naltrexone—Malnutrition—Carmustine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Naltrexone—Cough—Bleomycin—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Naltrexone—Angiopathy—Vincristine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Naltrexone—Diarrhoea—Teniposide—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Naltrexone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Naltrexone—Chest pain—Bleomycin—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Naltrexone—Myalgia—Bleomycin—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Naltrexone—Alopecia—Vincristine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Naltrexone—Back pain—Carmustine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Naltrexone—Discomfort—Bleomycin—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Naltrexone—Mental disorder—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Naltrexone—Chills—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Naltrexone—Alopecia—Mitoxantrone—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Naltrexone—Confusional state—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Naltrexone—Vision blurred—Carmustine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Naltrexone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Naltrexone—Tremor—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Naltrexone—Oedema—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Naltrexone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Naltrexone—Infection—Bleomycin—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Naltrexone—Back pain—Vincristine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Naltrexone—Vomiting—Teniposide—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Naltrexone—Agitation—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Naltrexone—Asthenia—Fludarabine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Naltrexone—Rash—Teniposide—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Naltrexone—Dermatitis—Teniposide—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Naltrexone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Naltrexone—Headache—Teniposide—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Naltrexone—Pruritus—Fludarabine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Naltrexone—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.002	0.002	CcSEcCtD
Naltrexone—Back pain—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Naltrexone—Anorexia—Bleomycin—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Naltrexone—Agitation—Vincristine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Naltrexone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Naltrexone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Naltrexone—Convulsion—Carmustine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Naltrexone—Hypertension—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Naltrexone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Naltrexone—Nausea—Teniposide—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Naltrexone—Chest pain—Carmustine—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Naltrexone—Myalgia—Carmustine—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Naltrexone—Anxiety—Carmustine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Naltrexone—Paraesthesia—Bleomycin—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Naltrexone—Malaise—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Naltrexone—Dyspnoea—Bleomycin—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Naltrexone—Convulsion—Vincristine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Naltrexone—Hypertension—Vincristine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Naltrexone—Confusional state—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Naltrexone—Oedema—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Naltrexone—Decreased appetite—Bleomycin—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Naltrexone—Myalgia—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Naltrexone—Cough—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Naltrexone—Infection—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Naltrexone—Vomiting—Fludarabine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Naltrexone—Convulsion—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Naltrexone—Rash—Fludarabine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Naltrexone—Dermatitis—Fludarabine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Naltrexone—Hypertension—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Naltrexone—Pain—Bleomycin—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Naltrexone—Headache—Fludarabine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Naltrexone—Tachycardia—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Naltrexone—Chest pain—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Naltrexone—Myalgia—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Naltrexone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Naltrexone—Anxiety—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Naltrexone—Lethargy—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Naltrexone—Discomfort—Mitoxantrone—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Naltrexone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Naltrexone—Oedema—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Naltrexone—Anorexia—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Naltrexone—Infection—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Naltrexone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Naltrexone—Confusional state—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Naltrexone—Nervous system disorder—Vincristine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Naltrexone—Oedema—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Naltrexone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Naltrexone—Nausea—Fludarabine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Naltrexone—Infection—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Naltrexone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Naltrexone—Shock—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Naltrexone—Urticaria—Bleomycin—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Naltrexone—Anorexia—Vincristine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Naltrexone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Naltrexone—Body temperature increased—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Naltrexone—Insomnia—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Naltrexone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Naltrexone—Irritability—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Naltrexone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Naltrexone—Paraesthesia—Carmustine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Naltrexone—Dyspnoea—Carmustine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Naltrexone—Somnolence—Carmustine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Naltrexone—Anorexia—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Naltrexone—Decreased appetite—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Naltrexone—Insomnia—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Naltrexone—Paraesthesia—Vincristine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Naltrexone—Constipation—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Naltrexone—Pain—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Naltrexone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Naltrexone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Naltrexone—Decreased appetite—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Naltrexone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Naltrexone—Somnolence—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Naltrexone—Feeling abnormal—Carmustine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Naltrexone—Fatigue—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Naltrexone—Asthenia—Bleomycin—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Naltrexone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Naltrexone—Pain—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Naltrexone—Constipation—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Naltrexone—Pruritus—Bleomycin—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Naltrexone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Naltrexone—Fatigue—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Naltrexone—Constipation—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Naltrexone—Pain—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Naltrexone—Abdominal pain—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Naltrexone—Body temperature increased—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Naltrexone—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Naltrexone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Naltrexone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Naltrexone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Naltrexone—Abdominal pain—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Naltrexone—Body temperature increased—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Naltrexone—Urticaria—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Naltrexone—Hypersensitivity—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Naltrexone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Naltrexone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Naltrexone—Pneumonia—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Naltrexone—Vomiting—Bleomycin—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Naltrexone—Infestation NOS—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Naltrexone—Infestation—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Naltrexone—Depression—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Naltrexone—Rash—Bleomycin—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Naltrexone—Dermatitis—Bleomycin—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Naltrexone—Asthenia—Carmustine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Naltrexone—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Naltrexone—Hypersensitivity—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Naltrexone—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Naltrexone—Epistaxis—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Naltrexone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Naltrexone—Asthenia—Vincristine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Naltrexone—Diarrhoea—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Naltrexone—Nausea—Bleomycin—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Naltrexone—Asthenia—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Naltrexone—Dizziness—Carmustine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Naltrexone—Diarrhoea—Vincristine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Naltrexone—Hepatitis—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Naltrexone—Pharyngitis—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Naltrexone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Naltrexone—Vomiting—Carmustine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Naltrexone—Dizziness—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Naltrexone—Rash—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Naltrexone—Dermatitis—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Naltrexone—Headache—Carmustine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Naltrexone—Eye disorder—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Naltrexone—Tinnitus—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Naltrexone—Vomiting—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Naltrexone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Naltrexone—Rash—Vincristine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Naltrexone—Dermatitis—Vincristine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Naltrexone—Headache—Vincristine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Naltrexone—Nausea—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Naltrexone—Angiopathy—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Naltrexone—Vomiting—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Naltrexone—Immune system disorder—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Naltrexone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Naltrexone—Rash—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Naltrexone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Naltrexone—Chills—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Naltrexone—Headache—Mitoxantrone—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Naltrexone—Alopecia—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Naltrexone—Nausea—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Naltrexone—Nausea—Mitoxantrone—lymphatic system cancer	0.000999	0.000999	CcSEcCtD
Naltrexone—Back pain—Methotrexate—lymphatic system cancer	0.000993	0.000993	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—lymphatic system cancer	0.000967	0.000967	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000953	0.000953	CcSEcCtD
Naltrexone—Malaise—Methotrexate—lymphatic system cancer	0.000926	0.000926	CcSEcCtD
Naltrexone—Cough—Methotrexate—lymphatic system cancer	0.000896	0.000896	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—lymphatic system cancer	0.000874	0.000874	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—lymphatic system cancer	0.000874	0.000874	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—lymphatic system cancer	0.000874	0.000874	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000868	0.000868	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—lymphatic system cancer	0.000864	0.000864	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—lymphatic system cancer	0.000845	0.000845	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Naltrexone—Infection—Methotrexate—lymphatic system cancer	0.000832	0.000832	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000822	0.000822	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—lymphatic system cancer	0.000814	0.000814	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00081	0.00081	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—lymphatic system cancer	0.000799	0.000799	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000763	0.000763	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000752	0.000752	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000747	0.000747	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—lymphatic system cancer	0.000745	0.000745	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000728	0.000728	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000723	0.000723	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—lymphatic system cancer	0.000722	0.000722	CcSEcCtD
Naltrexone—Pain—Methotrexate—lymphatic system cancer	0.000716	0.000716	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00069	0.00069	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000685	0.000685	CcSEcCtD
Naltrexone—Urticaria—Methotrexate—lymphatic system cancer	0.000666	0.000666	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000662	0.000662	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000662	0.000662	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000617	0.000617	CcSEcCtD
Naltrexone—Asthenia—Methotrexate—lymphatic system cancer	0.000601	0.000601	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—lymphatic system cancer	0.000593	0.000593	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000573	0.000573	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—lymphatic system cancer	0.000554	0.000554	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—lymphatic system cancer	0.000533	0.000533	CcSEcCtD
Naltrexone—Rash—Methotrexate—lymphatic system cancer	0.000528	0.000528	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—lymphatic system cancer	0.000528	0.000528	CcSEcCtD
Naltrexone—Headache—Methotrexate—lymphatic system cancer	0.000525	0.000525	CcSEcCtD
Naltrexone—Nausea—Methotrexate—lymphatic system cancer	0.000498	0.000498	CcSEcCtD
